Compare · LLY vs ONC
LLY vs ONC
Side-by-side comparison of Eli Lilly and Company (LLY) and BeOne Medicines Ltd. (ONC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LLY and ONC operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.18T, about 27.7x ONC ($42.53B).
- Over the past year, LLY is up 56.5% and ONC is up 17.0% - LLY leads by 39.5 points.
- LLY has been more active in the news (25 items in the past 4 weeks vs 3 for ONC).
- LLY has more recent analyst coverage (25 ratings vs 7 for ONC).
- Company
- Eli Lilly and Company
- BeOne Medicines Ltd.
- Price
- $1257.32+0.45%
- $369.27-1.29%
- Market cap
- $1.18T
- $42.53B
- 1M return
- +9.10%
- +4.46%
- 1Y return
- +56.51%
- +17.01%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2016
- News (4w)
- 25
- 3
- Recent ratings
- 25
- 7
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest LLY
- Lilly confirms date and conference call for third-quarter 2026 financial results announcement
- New composite outcomes data show patients treated with Lilly's Omvoh (mirikizumab-mrkz) achieved comprehensive corticosteroid-free disease control in ulcerative colitis and corticosteroid-free deep remission in Crohn's disease at one year
- Nasdaq Sheds 1.65% as Russell 2000 Sinks to RSI 28, Oil Climbs While Gold and Silver Slide
- Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda
- Record Highs Beckon for Big Caps as Small Caps Lag and Deal Flow Builds
- New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) advance understanding of the interconnected immune and metabolic biology in adults with psoriasis and obesity
- SEC Form 3 filed by Eli Lilly and Company
- Lilly to present new data across its dermatology portfolio with 21 presentations at Fall Clinical 2026, in pursuit of advancing care for chronic skin conditions
- Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLL
- Lilly's oral GLP-1, Foundayo (orforglipron), was associated with significant reductions in predicted long-term risk of type 2 diabetes and cardiovascular disease
Latest ONC
- SEC Form 4 filed by BeOne Medicines Ltd.
- SVP, General Counsel Lee Chan Henry sold $418,125 worth of American Depositary Shares (1,115 units at $375.00) as part of a pre-agreed trading plan, closing all direct ownership in the company (SEC Form 4)
- Chair, Scientific Advisory Brd Wang Xiaodong exercised 31,028 units of American Depositary Shares at a strike of $36.90 and sold $11,318,558 worth of American Depositary Shares (31,028 units at $364.79) as part of a pre-agreed trading plan (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13D/A filed by BeOne Medicines Ltd.
- Chair, Scientific Advisory Brd Wang Xiaodong sold $13,366,092 worth of American Depositary Shares (38,287 units at $349.10) as part of a pre-agreed trading plan and exercised 31,027 units of American Depositary Shares at a strike of $36.90, closing all direct ownership in the company (SEC Form 4)
- Principal Accounting Officer Ball Titus B. sold $46,974 worth of American Depositary Shares (132 units at $355.86), closing all direct ownership in the company (SEC Form 4) (for withholding tax)
- BeOne Medicines to Present at the Morgan Stanley Annual Global Healthcare Conference
- BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines
- BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer
- President and COO Wu Xiaobin sold $106,400 worth of American Depositary Shares (280 units at $380.00) as part of a pre-agreed trading plan, closing all direct ownership in the company (SEC Form 4)